Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease
source: Clinical Infectious Diseases
year: 2017
authors: Moon J, Hyland RH, Zhang F, Brainard DM, Lanzkron S, McHutchison JG, Sulkowski M
summary/abstract:Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed dose combination, ledipasvir and sofosbuvir for 12 weeks in this population.
organization: Johns Hopkins University School of Medicine, Baltimore; Gilead Sciences, Inc., Foster City USADOI: 10.1093/cid/cix441
read more full text
Related Content
-
Sickle-Cell Patients See Hope in CRISPRSickle-cell disease is one of the most c...
-
Sickle cell cure is real, as this Kansas patient provesIntense pain. Fatigue. Repeated infectio...
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
HydroxyureaHydroxyurea (Hydrea) is used alone or wi...
-
Health disparity in hematopoietic cell transplantation for sickle cell disease: Analyzing the association of insuran...The impact of racial and socioeconomic s...
-
University Hospitals program uses music to teach about sickle cell (photos, video)The study looked at Seidman's BEATS (Bui...
-
The Upside of Bad GenesFor the last two decades, they’ve had ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
+myBinder